is an antibody binding moiety comprising a hapten which is capable of binding to an antibody in said patient or subject;
L1 is a linker molecule which chemically links

to CT, L2 or

[0009]

in said compound;
L2 is a linker molecule which chemically links

to CT, L1 or

[0010]

in a molecule;
CT is a bond or a connector molecule which links L1 and/or L2 to



;

Each j is independently 0, 1, 2, 3, 4 or 5 (preferably 0 or 1, more preferably 1);
Each k is independently 0, 1, 2, 3, 4 or 5 (preferably 0 or 1, more preferably 1), with the proviso that k and/or j are other than 0 when CT is a bond; and
Each m and n is independently an integer from 1 to 15, 1 to 10, 1 to 5, 1 to 3, 2 to 3, 2 to 5, 1 to 2 or 1 (preferably m and n are each 1),
or a pharmaceutically acceptable salt, solvate or polymorph thereof.

[0011] In further aspects of the present invention, precursor compounds (as described above or otherwise as described herein) are reacted or complexed with urokinase-type plasminogen activator (UPA) according to the present invention to provide ARM-U compounds represented by the chemical formula:



[0012] Where UPA is urokinase-type plasminogen activator (UPA) as otherwise described herein,

is a

group which has covalently or non-covalently (preferably covalently bound) to UPA and each of

,

L1, CT, L2,

[0013]

,

j, k, m and n is the same as above or as otherwise described herein.

[0014] In certain embodiments of the present invention, compounds according to the present invention (i.e., compounds which are unbound to UPA or are precursors to compounds which are bound to UPA) may be represented by the chemical formula:



Where T is group which binds to UPA, preferably covalently, and is preferably a R^e group or an amino acid group according to the chemical structure:



;

R^{AA} is a sidechain of an amino acid, preferably a side chain of lysine or arginine



;